A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03378635 |
Recruitment Status :
Completed
First Posted : December 20, 2017
Results First Posted : May 10, 2021
Last Update Posted : June 10, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypoglycemia Diabetes Mellitus, Type 1 | Drug: Dasiglucagon Drug: GlucaGen Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 170 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen |
Actual Study Start Date : | December 7, 2017 |
Actual Primary Completion Date : | April 27, 2018 |
Actual Study Completion Date : | May 25, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Dasiglucagon
Single fixed dose (s.c.injection) of dasiglucagon
|
Drug: Dasiglucagon
Glucagon analog
Other Name: ZP4207 |
Placebo Comparator: Placebo
Single fixed dose (s.c.injection) of placebo
|
Drug: Placebo
Placebo for dasiglucagon
Other Name: Placebo for dasiglucagon |
Active Comparator: GlucaGen®
Single fixed dose (s.c.injection) of GlucaGen®
|
Drug: GlucaGen
Native glucagon
Other Name: GlucaGen HypoKit |
- Time to Plasma Glucose Recovery [ Time Frame: 0-45 minutes after dosing ]Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
- Plasma Glucose Recovery [ Time Frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection ]Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.
- Plasma Glucose Changes From Baseline [ Time Frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection ]Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose
- Time to Target [ Time Frame: 0-45 minutes after dosing ]Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
- Pharmacodynamics - Area Under the Effect Curve [ Time Frame: 0-30 minutes after dosing ]Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.
- Pharmacokinetics - Area Under the Plasma Concentration Curve [ Time Frame: 0-90 minutes after dosing ]Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
- Pharmacokinetics - Area Under the Plasma Concentration Curve [ Time Frame: 0-120 minutes after dosing ]Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
- Pharmacokinetics - Maximum Plasma Concentration [ Time Frame: 0-120 minutes after dosing ]Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
- Pharmacokinetics - Time to Maximum Plasma Concentration [ Time Frame: 0-120 minutes after dosing ]Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
- Immunogenicity - Occurence of Anti-drug Antibodies [ Time Frame: 28 days ]Occurence of antibodies against dasiglucagon/GlucaGen
- Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure [ Time Frame: 0-45 minutes after dosing ]Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous
- Time to First Rescue Infusion of IV Glucose [ Time Frame: 0-45 minutes after dosing ]Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female or male subjects with type 1 diabetes mellitus (T1DM) for at least 1 year, diagnostic criteria as defined by the American Diabetes Association
- Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening
- Hemoglobin A1c <10%
Exclusion Criteria:
- Previously treated with dasiglucagon (previously referred to as ZP4207)
- Known or suspected allergy to trial product(s) or related products
- Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating.
- History of hypoglycemic events associated with seizures in the last year prior to screening
- History of severe hypoglycemia in the last month prior to screening
- Active malignancy within the last 5 years
- Current bleeding disorder, including anti-coagulant treatment
- Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor)
- Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial
- Clinically significant abnormal ECG at screening as judged by the investigator
- Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening
- Surgery or trauma with significant blood loss within the last 2 months prior to screening
- A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378635
United States, California | |
ProSciento | |
Chula Vista, California, United States, 91911 | |
Austria | |
Clinical Research Center, Medizinische Universität Graz | |
Graz, Austria | |
Canada | |
LMC Diabetes & Manna Research | |
Toronto, Canada | |
Germany | |
Profil | |
Mainz, Germany | |
Profil | |
Neuss, Germany |
Study Director: | Christina Sylvest, MSc Pharm | Zealand Pharma |
Documents provided by Zealand Pharma:
Responsible Party: | Zealand Pharma |
ClinicalTrials.gov Identifier: | NCT03378635 |
Other Study ID Numbers: |
ZP4207-16137 |
First Posted: | December 20, 2017 Key Record Dates |
Results First Posted: | May 10, 2021 |
Last Update Posted: | June 10, 2021 |
Last Verified: | May 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Dasiglucagon Glucagon analog |
Diabetes Mellitus Diabetes Mellitus, Type 1 Hypoglycemia Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Glucagon Gastrointestinal Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |